Albumin injection: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Albumin injection''' is a protein extracted from human blood, which, when injected intravenously as a 5% solution, increases the volume and osmotic pressure of plasma. The primary indication is treatment of [[hypovolemia]], but it has some indications for severe edema secondary to [[ | '''Albumin injection''' is a protein extracted from human blood, which, when injected intravenously as a 5% solution, increases the volume and osmotic pressure of plasma. The primary indication is treatment of [[hypovolemia]], but it has some indications for severe edema secondary to [[kidney]] or [[liver]] disease. | ||
Since it is a natural blood product, it carries some risk of antigenicity and a low risk of infection; the supply also can be unpredictable. The [[dextran]]s, one class of synthetic plasma expander, has no infection risk, but has its own problems of antigenicity. [[Hetastarch]] is considerably cheaper and has negligible risk of immune reaction. <ref>{{citation | Since it is a natural blood product, it carries some risk of antigenicity and a low risk of infection; the supply also can be unpredictable. The [[dextran]]s, one class of synthetic plasma expander, has no infection risk, but has its own problems of antigenicity. [[Hetastarch]] is considerably cheaper and has negligible risk of immune reaction. <ref>{{citation | ||
Revision as of 21:59, 21 December 2010
Albumin injection is a protein extracted from human blood, which, when injected intravenously as a 5% solution, increases the volume and osmotic pressure of plasma. The primary indication is treatment of hypovolemia, but it has some indications for severe edema secondary to kidney or liver disease.
Since it is a natural blood product, it carries some risk of antigenicity and a low risk of infection; the supply also can be unpredictable. The dextrans, one class of synthetic plasma expander, has no infection risk, but has its own problems of antigenicity. Hetastarch is considerably cheaper and has negligible risk of immune reaction. [1]
References
- ↑ Wong YY, Abramowitz PW, Mansur JM (January 1987), "(Abstract) Changing use patterns of plasma volume expanders through educational intervention.", Am J Hosp Pharm 44 (1): 102-5.